Adalimumab: Difference between revisions
From IDWiki
(Created page with "* Human IgG1 monoclonal antibody against TNF-α * Indications include JIA, RA, Crohn disease, ankylosing spondylitis, chronic plaque psoriasis, and psori...") |
No edit summary |
||
| Line 1: | Line 1: | ||
| − | * Human IgG1 monoclonal antibody against TNF-α |
+ | * Human IgG1 monoclonal antibody against [[Tumour necrosis factor-α inhibitors|TNF-α]] |
* Indications include [[JIA]], [[RA]], [[Crohn disease]], [[ankylosing spondylitis]], chronic plaque [[psoriasis]], and [[psoriatic arthritis]] |
* Indications include [[JIA]], [[RA]], [[Crohn disease]], [[ankylosing spondylitis]], chronic plaque [[psoriasis]], and [[psoriatic arthritis]] |
||
* Infectious complications include bacterial infections (including severe [[pneumonia]]), [[TB]], [[candidiasis]], [[CMV]], [[toxoplasmosis]], and [[nocardiosis]] |
* Infectious complications include bacterial infections (including severe [[pneumonia]]), [[TB]], [[candidiasis]], [[CMV]], [[toxoplasmosis]], and [[nocardiosis]] |
||
Revision as of 20:42, 16 March 2022
- Human IgG1 monoclonal antibody against TNF-α
- Indications include JIA, RA, Crohn disease, ankylosing spondylitis, chronic plaque psoriasis, and psoriatic arthritis
- Infectious complications include bacterial infections (including severe pneumonia), TB, candidiasis, CMV, toxoplasmosis, and nocardiosis
